Chemeleon
Brooklyn
About Chemeleon
Chemeleon has created a novel diagnostic platform, combining silicon photonics with high-affinity molecular receptors to create an instrument-free, point-of-care diagnostic that provides a semi-quantitative colorimetric readout in minutes with lab-grade precision. For life-threatening conditions where every minute counts, like acute myocardial infarction (AMI), our assay can detect and quantify concentrations of protein biomarkers, like troponin, to diagnose AMI in under two minutes with high precision. This rapid, cost-effective, and highly accurate test will enable EMTs, paramedics and emergency department staff to quickly diagnose AMI and initiate critical interventions, saving lives and drastically reducing healthcare costs. We’re initially targeting the $5.9 billion high-sensitivity cardiac troponin assay market and expanding to other indications in the $15 billion rapid acute care diagnostic market with broader applications in the $62.3 billion global point-of-care diagnostic market. We secured significant seed funding, including over $2 million in NSF and NIH Phase I and II SBIR grants, have strong licensing interest from several of the top diagnostics companies, and are currently looking for partners and investors for our $10 million Series A round to join us in revolutionizing point-of-care diagnostics.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $6.1M
- Funding stage: Seed
- Last round: Grant (Jan 2023)
- Website: chemeleon.com
- Phone: 6463698010
Industries & Categories
Chemical, Health Care, Health Diagnostics, Medical Device, Nanotechnology
Social Profiles
Canonical: https://fsome.com/organization/chemeleon-86422 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.